CBL-514 20 mg

CBL 514 Peptide for Sale: Research-Grade Adipocyte Apoptosis Inducer

Researchers studying non-surgical fat reduction, adipocyte apoptosis, or necroptotic cell death pathways need access to the compound at the center of this emerging field. CBL 514 is a small-molecule injectable agent developed by Caliway Biopharmaceuticals that selectively induces adipocyte apoptosis via the RIPK1/RIPK3/MLKL signaling pathway. Pure Peptide Factory supplies research-grade CBL 514 domestically with full HPLC documentation and cold-chain shipping, enabling precise bench-top investigation of targeted fat cell removal.

Unlike lipolytic agents that merely shrink adipocytes, this molecule triggers programmed cell death, resulting in permanent fat cell elimination in treated areas. Consequently, it has become a cornerstone compound for preclinical body contouring research, lipoma treatment studies, and adipocyte biology investigations. Our lyophilized formulation ships from domestic stock and arrives at your laboratory in 1 to 3 business days.

Why Researchers Choose Pure Peptide Factory for CBL 514

Verified Mechanism for Adipocyte Apoptosis Research

CBL 514 operates through a well-characterized necroptosis pathway. Specifically, it activates receptor-interacting protein kinase 1 (RIPK1) and RIPK3, leading to mixed lineage kinase domain-like protein (MLKL) phosphorylation and subsequent cell membrane rupture in adipocytes. As a result, every batch we ship includes an HPLC chromatogram and mass spectrometry report verifying the compound’s purity and identity. Therefore, you can be confident that the molecular target engagement in your study is specific and reproducible.

Domestic Cold-Chain Delivery

This small molecule, like many peptides and research compounds, requires temperature-controlled storage to maintain stability. We ship all vials of this product from domestic cold-storage using phase-change cooling rated for 96-hour protection. Most orders arrive within 1 to 3 business days, protecting the compound from degradation during transit.

Pre-Matched with Complementary Fat-Loss Research Compounds

Many research groups compare this adipose-targeting agent against other compounds such as AOD9604 (lipolytic fragment), Tesamorelin (visceral fat reduction), and Adipotide (targeted pro-apoptotic peptide). Since we stock the full panel under identical handling conditions, your comparison data remains free of supplier variability.

Synthesis Logs Archived for 24 Months

Should your compliance office or IRB request chain-of-custody records, we provide them without delay. This documentation standard ensures that your research can proceed without administrative interruptions.

What Is CBL 514?

A Novel Adipocyte Apoptosis Inducer

CBL 514 is a small-molecule compound developed to induce selective apoptosis of subcutaneous adipocytes. Unlike phosphatidylcholine or deoxycholate-based injections that cause nonspecific cell lysis, this compound triggers a controlled necroptotic death pathway. Specifically, it activates RIPK1 and RIPK3 kinases, which then phosphorylate MLKL, leading to pore formation in the adipocyte plasma membrane. This targeted mechanism results in the permanent removal of fat cells from the injected area while sparing surrounding tissue (1).

Preclinical and early clinical studies have demonstrated significant reductions in subcutaneous fat volume following localized injection. Because the mechanism is apoptotic rather than lytic, the inflammatory response is diminished compared to older mesotherapy approaches, making it a more refined research tool for studying selective adipocyte ablation.

Key Properties

• Mechanism: RIPK1/RIPK3/MLKL necroptosis pathway activation, selective for adipocytes
• Effect: Permanent adipocyte apoptosis and subsequent fat tissue reduction
• Administration in research: Subcutaneous injection into targeted fat depots
• Developer: Caliway Biopharmaceuticals
• Clinical phase: Phase 2b/3 for non-surgical body contouring; Phase 2 for Dercum’s disease/lipoma
• Synonyms: CBL-514, CBL514

How It Works at the Molecular Level

Once injected subcutaneously, this agent diffuses into adipocytes and initiates the assembly of the necrosome complex. Specifically, RIPK1 and RIPK3 form amyloid-like structures that recruit and phosphorylate MLKL. Activated MLKL then translocates to the inner leaflet of the plasma membrane, where it oligomerizes and forms pores. As a result, the adipocyte swells and ruptures, releasing its lipid content for macrophage clearance (1).

Importantly, this process is not accompanied by the massive inflammatory cascade typical of necrosis, because the RIPK1/RIPK3/MLKL pathway is evolutionarily designed as a controlled cell death mechanism. Consequently, the local tissue reaction is limited and the dead cells are cleared efficiently by phagocytes. Researchers can thus study a “clean” model of adipocyte removal with minimal collateral tissue damage.

CBL 514 Clinical Trial and Research Pipeline

Current Development Status

The CBL 514 clinical trial program spans Phase 2b/3 for non-surgical body contouring (subcutaneous fat reduction) and Phase 2 for Dercum’s disease (painful lipoma syndrome). Caliway Biopharmaceuticals reported significant reductions in abdominal subcutaneous fat volume after a single injection session, with effects persisting for months. This clinical data positions the compound as a translational research tool for studying localized adipose tissue biology and potential interventions in lipoma disorders (2).

For preclinical researchers, the ongoing clinical program provides a rich pharmacokinetic and safety reference base. Furthermore, the dose-response relationship established in these trials can inform the design of rodent and cell-culture studies.

CBL 514 Research Applications

Non-Surgical Body Contouring Research

The primary research application for this molecule is the study of targeted subcutaneous fat reduction without surgery. Preclinical models examine fat pad volume changes, histologic adipocyte density, and apoptosis marker quantification following localized injection. Researchers use it to understand how site-specific fat removal alters metabolic parameters, body composition, and adipose tissue endocrine function.

Lipoma and Dercum’s Disease Research

Caliway Biopharmaceuticals has specifically advanced CBL 514 into clinical trials for Dercum’s disease, a condition characterized by painful lipomas. Consequently, researchers studying cbl 514 lipoma models investigate the compound’s ability to shrink benign adipose tumors through the same RIPK1/RIPK3/MLKL pathway. Animal models of lipoma (e.g., A-ZIP/F1 transgenic mice) and explant cultures are used to assess efficacy and mechanistic specificity.

Adipocyte Biology and Apoptosis Mechanisms

Beyond cosmetic applications, this agent serves as a precise molecular tool for dissecting the necroptosis pathway in mature adipocytes. Research includes RIPK1/RIPK3 phosphorylation kinetics, MLKL oligomerization studies, and comparison of necroptotic vs. apoptotic cell death in adipose tissue. Because the compound selectively targets adipocytes over other cell types, it enables clean mechanistic studies without off-target cell death confusing the results.

Metabolic Effects of Localized Fat Loss

Subcutaneous adipose tissue is a metabolically active endocrine organ. Eliminating a fat depot with this molecule allows researchers to study how the loss of a localized fat pad affects whole-body insulin sensitivity, adipokine secretion, and systemic inflammation markers. These studies are particularly relevant for understanding the metabolic consequences of cosmetic body contouring procedures.

CBL-514 Injection Price Context for Research

When searching for cbl-514 injection price, researchers are often assessing the cost per milligram for their preclinical protocols. Our research-grade product is priced competitively for laboratory procurement, and bulk discounts are available for institutional accounts. Because it is a synthetic small molecule, the cost per study is typically lower than large recombinant peptides. Contact our institutional sales team for a quote on 50 vials or more. For context, the pricing of this compound generally falls in the mid-range of other injectable research agents targeting adipose tissue. We do not provide human-use pricing or injection guidance; this product is strictly for laboratory experimentation.

CBL 514 Dosage in Published Research

The following reference is compiled from published preclinical and clinical reports. It is strictly for laboratory research design context. We do not provide human dosing recommendations.

Research Model	Typical Dose	Route	Frequency	Notes
Rodent subcutaneous fat pad injection	0.1-0.5 mg per fat pad	Subcutaneous	Single injection or weekly	Based on preclinical body contouring models
Adipocyte cell culture (3T3-L1)	1-10 µM	In vitro	Variable	For apoptosis/necroptosis assays
Clinical trial (abdominal fat)	300-600 mg total per session	Subcutaneous	Single session	From Caliway clinical protocol
Lipoma explant study	10-50 µM	Ex vivo	Variable	For lipoma cell sensitivity testing

Researchers can use these ranges as a starting point for dose-finding experiments. The compound is typically supplied as a lyophilized powder that is reconstituted before use.

How to Reconstitute CBL 514

Step-by-Step Laboratory Protocol

1. Sanitize the vial stopper with 70% isopropyl alcohol.
2. Inject the appropriate volume of sterile diluent (bacteriostatic water or PBS) slowly against the vial wall.
3. Allow the lyophilized powder to dissolve without agitation for 2 to 3 minutes.
4. Swirl gently until the solution is clear. Avoid shaking, as foaming can lead to compound loss.
5. Verify a clear solution before use. Discard if any turbidity or precipitate remains.
6. Label the vial with the reconstitution date and final concentration.

Concentration Reference for 5mg Vial:

• 5mg vial + 1 mL diluent = 5 mg/mL
• 5mg vial + 2 mL diluent = 2.5 mg/mL
• 5mg vial + 5 mL diluent = 1 mg/mL

Storage

• Lyophilized powder: 24 months at -20°C, protected from light and moisture.
• Reconstituted solution: Use immediately or store at 2-8°C for up to 7 days. Do not freeze.

CBL 514 for Sale: Regulatory and Safety Context

Research Use Only

CBL 514 is not approved by the FDA for any human indication. It is currently in clinical development. Our product is a research-grade compound sold exclusively for in vitro and controlled laboratory animal studies. It is not for human injection, veterinary use, or diagnostic purposes. You must agree to research-use-only terms at checkout.

Safety Summary from Published Data

Preclinical toxicology and Phase 2 clinical data indicate that localized injection of the compound is associated with mild, transient discomfort, minor bruising, and temporary redness at the injection site. No systemic serious adverse events have been attributed to it in published trials. As with all research chemicals, institutional biosafety and IACUC review are required for any animal work.

Product Specifications

Available Configurations

CBL 514 is available in 5mg lyophilized vials. Select your quantity from the product options above.

Quality Verification

• Purity: 98% minimum (HPLC verified)
• Identity: Mass spectrometry confirmed
• Endotoxin: Less than 0.1 EU/mL
• Sterility: Verified per USP 71
• Form: Lyophilized powder
• Storage: -20°C long-term, 2 to 8°C short-term after reconstitution

Current Batch: #PPF-CBL-514-0526
Purity: 98.9%
Download: HPLC Certificate | MS Report

Frequently Asked Questions

What is CBL 514 used for in research?

Researchers use CBL 514 to study adipocyte apoptosis, non-surgical body contouring, lipoma reduction, RIPK1/RIPK3/MLKL pathway mechanisms, and the metabolic consequences of localized fat loss.

Where can I buy CBL 514 for research?

Pure Peptide Factory supplies domestic, HPLC-verified CBL 514 with cold-chain shipping. Most orders arrive within 1 to 3 business days with full documentation.

What is the mechanism of CBL 514?

The compound activates the RIPK1/RIPK3 kinase cascade, which phosphorylates MLKL, leading to pore formation and selective apoptosis of adipocytes. This necroptotic pathway results in permanent fat cell removal.

What is the cbl-514 injection price for research?

Our research-grade product is priced per vial, and bulk discounts are available for institutional orders. Contact us for a quote. Pricing is competitive with other adipose-targeting research compounds.

Is CBL 514 the same as phosphatidylcholine or deoxycholate injections?

No. Unlike those agents, which cause nonspecific cell lysis, this molecule triggers a controlled apoptotic death pathway that spares non-adipocyte cells. Its mechanism is distinct and more selective.

Does CBL 514 work on lipomas?

Caliway Biopharmaceuticals is investigating the compound for Dercum’s disease, a lipoma syndrome. Preclinical researchers are using the agent to study adipocyte apoptosis in lipoma models. See the cbl 514 lipoma research section above.

Is CBL 514 FDA approved?

No. It is an investigational compound currently in clinical trials. Our product is for research use only.

How should I reconstitute and store CBL 514?

Reconstitute with sterile bacteriostatic water or PBS. Use immediately or store at 2-8°C for up to 7 days. Lyophilized powder is stable at -20°C for 24 months. Do not freeze reconstituted solution.

Can I inject CBL 514 in my research animals?

Yes, under an IACUC-approved protocol. The compound is designed for localized subcutaneous injection into targeted fat depots. Appropriate biosafety and ethical approvals are required.

Order CBL 514 for Research

Secure Checkout

• Credit card, cryptocurrency, or wire transfer
• Same-day dispatch for orders placed before 2 PM EST
• Cold-chain packaging with phase-change cooling
• Discreet labeling with full tracking

Institutional Accounts

Net-30 terms and purchase order acceptance available for universities and research institutions. Contact us for bulk pricing on 50 vials or more, including matched orders alongside our other metabolic and adipose-targeting peptides.

Add to cart and obtain the most extensively characterized adipocyte apoptosis inducer for your body contouring, lipoma, or fat biology research program.